Tag: HR+/HER2- breast cancer

Home / HR+/HER2- breast cancer

Categories

Capivasertib with fulvestrant is approved by the USFDA for breast cancer treatment

Capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with fulvestrant was approved by the Food and Drug Administration on November 16, 2023, for adult patients with hormone receptor (HR)...
hr-her2-breast-cancer

Scan the code